CASSAVA SCIENCES INC (SAVA)
US14817C1071 - Common Stock
We assign a fundamental rating of 2 out of 10 to SAVA. SAVA was compared to 193 industry peers in the Pharmaceuticals industry. SAVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SAVA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SAVA had negative earnings in the past year.
In the past year SAVA has reported a negative cash flow from operations.
In the past 5 years SAVA always reported negative net income.
In the past 5 years SAVA always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -7.89%, SAVA is in the better half of the industry, outperforming 72.63% of the companies in the same industry.
With a decent Return On Equity value of -10.60%, SAVA is doing good in the industry, outperforming 76.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.89% | ||
| ROE | -10.6% | ||
| ROIC | N/A |
ROA(3y)-36.24%
ROA(5y)-27.03%
ROE(3y)-39%
ROE(5y)-28.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SAVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SAVA has been increased compared to 1 year ago.
SAVA has more shares outstanding than it did 5 years ago.
SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.26, we must say that SAVA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SAVA (-2.26) is comparable to the rest of the industry.
There is no outstanding debt for SAVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.26 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SAVA has a Current Ratio of 3.55. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.55, SAVA perfoms like the industry average, outperforming 53.68% of the companies in the same industry.
A Quick Ratio of 3.55 indicates that SAVA has no problem at all paying its short term obligations.
SAVA has a Quick ratio (3.55) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.55 | ||
| Quick Ratio | 3.55 |
3. Growth
3.1 Past
SAVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.84%, which is quite impressive.
EPS 1Y (TTM)83.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SAVA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.18% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.3%
EPS Next 2Y34.49%
EPS Next 3Y26.91%
EPS Next 5Y4.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SAVA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAVA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SAVA's earnings are expected to grow with 26.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.49%
EPS Next 3Y26.91%
5. Dividend
5.1 Amount
SAVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CASSAVA SCIENCES INC
NASDAQ:SAVA (12/27/2024, 4:01:06 PM)
After market: 2.5 0 (0%)2.5
-0.09 (-3.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners29.17%
Inst Owner Change3.9%
Ins Owners9.07%
Ins Owner Change0%
Market Cap119.95M
Analysts45.71
Price Target118.32 (4632.8%)
Short Float %40.95%
Short Ratio2.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.62%
Min EPS beat(2)35.38%
Max EPS beat(2)131.86%
EPS beat(4)4
Avg EPS beat(4)99.15%
Min EPS beat(4)5.73%
Max EPS beat(4)223.62%
EPS beat(8)6
Avg EPS beat(8)53.75%
EPS beat(12)6
Avg EPS beat(12)34.18%
EPS beat(16)8
Avg EPS beat(16)17.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.19%
EPS NY rev (1m)38.7%
EPS NY rev (3m)38.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.72 | ||
| P/tB | 0.72 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.89% | ||
| ROE | -10.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-36.24%
ROA(5y)-27.03%
ROE(3y)-39%
ROE(5y)-28.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.99% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.55 | ||
| Quick Ratio | 3.55 | ||
| Altman-Z | -2.26 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1558.25%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.92%
EPS Next Y52.3%
EPS Next 2Y34.49%
EPS Next 3Y26.91%
EPS Next 5Y4.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.48%
OCF growth 3YN/A
OCF growth 5YN/A